Company Filing History:
Years Active: 2022-2023
Title: Innovations of Shu-Lun Tang in Therapeutic Antibodies
Introduction
Shu-Lun Tang is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of therapeutic antibodies, focusing on their application in cancer treatment. With a total of 2 patents, his work is pivotal in advancing medical science.
Latest Patents
Shu-Lun Tang's latest patents involve humanized antibodies and antigen-binding fragments that specifically target biantennary Lewis antigens. These antigens are expressed in various cancers, making the disclosed antibodies crucial for targeting antigen-expressing cells. The patents also cover polynucleotides, vectors, and host cells for producing these antibodies and their fragments. Furthermore, the patents detail pharmaceutical compositions, methods of treatment, and detection, showcasing the versatility and importance of these innovations in combating cancer.
Career Highlights
Shu-Lun Tang is associated with Glyconex, Inc., where he continues to develop groundbreaking therapeutic solutions. His expertise in antibody technology has positioned him as a key figure in the biotechnology sector.
Collaborations
He collaborates with notable colleagues, including Tong-Hsuan Chang and Mei-Chun Yang, to further enhance the research and development of therapeutic antibodies.
Conclusion
Shu-Lun Tang's innovative work in therapeutic antibodies represents a significant advancement in cancer treatment. His contributions are vital for the ongoing development of targeted therapies that can improve patient outcomes.